Cargando…
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000479/ https://www.ncbi.nlm.nih.gov/pubmed/32072141 http://dx.doi.org/10.1097/HS9.0000000000000325 |
| _version_ | 1783494049874837504 |
|---|---|
| author | Stevens, Wendy B.C. Bakunina, Katerina Cuijpers, Marloes Chamuleau, Martine Beeker, Aart Fijnheer, Rob Hebart, Holger Visser, Hein P.J. Doorduijn, Jeanette K. Linton, Kim Dreyling, Martin de Jong, Daphne Kersten, Marie José |
| author_facet | Stevens, Wendy B.C. Bakunina, Katerina Cuijpers, Marloes Chamuleau, Martine Beeker, Aart Fijnheer, Rob Hebart, Holger Visser, Hein P.J. Doorduijn, Jeanette K. Linton, Kim Dreyling, Martin de Jong, Daphne Kersten, Marie José |
| author_sort | Stevens, Wendy B.C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7000479 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70004792020-02-18 HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma Stevens, Wendy B.C. Bakunina, Katerina Cuijpers, Marloes Chamuleau, Martine Beeker, Aart Fijnheer, Rob Hebart, Holger Visser, Hein P.J. Doorduijn, Jeanette K. Linton, Kim Dreyling, Martin de Jong, Daphne Kersten, Marie José Hemasphere Letter Wolters Kluwer Health 2020-01-03 /pmc/articles/PMC7000479/ /pubmed/32072141 http://dx.doi.org/10.1097/HS9.0000000000000325 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spellingShingle | Letter Stevens, Wendy B.C. Bakunina, Katerina Cuijpers, Marloes Chamuleau, Martine Beeker, Aart Fijnheer, Rob Hebart, Holger Visser, Hein P.J. Doorduijn, Jeanette K. Linton, Kim Dreyling, Martin de Jong, Daphne Kersten, Marie José HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_full | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_fullStr | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_full_unstemmed | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_short | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_sort | hovon110/rebel study: results of the phase i part of a randomized phase i/ii study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000479/ https://www.ncbi.nlm.nih.gov/pubmed/32072141 http://dx.doi.org/10.1097/HS9.0000000000000325 |
| work_keys_str_mv | AT stevenswendybc hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT bakuninakaterina hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT cuijpersmarloes hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT chamuleaumartine hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT beekeraart hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT fijnheerrob hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT hebartholger hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT visserheinpj hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT doorduijnjeanettek hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT lintonkim hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT dreylingmartin hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT dejongdaphne hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT kerstenmariejose hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma |